Luye Pharma Group Ltd Cash Flow Conversion Efficiency
Luye Pharma Group Ltd cash flow conversion efficiency. Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has a cash flow conversion efficiency ratio of 0.028x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€344.86 Million ≈ $403.18 Million USD) by net assets (€12.19 Billion ≈ $14.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Luye Pharma Group Ltd (2016–2025)
Cash flow conversion efficiency of Luye Pharma Group Ltd from 2016 to 2025. This chart illustrates how Luye Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Luye Pharma Group Ltd stock price today for real-time trading data and today's change.
Luye Pharma Group Ltd Cash Flow Conversion Ratio Explained
Luye Pharma Group Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Luye Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Luye Pharma Group Ltd ranked by their cash flow conversion efficiency. Also see LUP stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nuveen Select Tax-Free Income Portfolio
NYSE:NXP
|
-0.002x |
|
ASRock Inc
TW:3515
|
-0.040x |
|
Hunan New Wellful Co Ltd
SHG:600975
|
0.064x |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
0.048x |
|
Zhejiang Kaier New Materials
SHE:300234
|
0.026x |
|
Hainan Development Holdings Nanhai Co Ltd
SHE:002163
|
-0.094x |
|
Cimsa Cimento Sanayi ve Ticaret AS
IS:CIMSA
|
0.029x |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
0.050x |
Annual Cash Flow Conversion Efficiency for Luye Pharma Group Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Luye Pharma Group Ltd from 2016 to 2025. Review Luye Pharma Group Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €18.36 Billion ≈ $21.46 Billion |
€1.78 Billion ≈ $2.08 Billion |
0.097x | +812.06% |
| 2024-12-31 | €15.75 Billion ≈ $18.42 Billion |
€167.76 Million ≈ $196.13 Million |
0.011x | -90.97% |
| 2023-12-31 | €13.53 Billion ≈ $15.82 Billion |
€1.60 Billion ≈ $1.87 Billion |
0.118x | -21.26% |
| 2022-12-31 | €11.04 Billion ≈ $12.91 Billion |
€1.65 Billion ≈ $1.93 Billion |
0.150x | +648.50% |
| 2021-12-31 | €9.11 Billion ≈ $10.66 Billion |
€182.37 Million ≈ $213.21 Million |
0.020x | -84.32% |
| 2020-12-31 | €8.10 Billion ≈ $9.47 Billion |
€1.03 Billion ≈ $1.21 Billion |
0.128x | -15.94% |
| 2019-12-31 | €9.37 Billion ≈ $10.96 Billion |
€1.42 Billion ≈ $1.66 Billion |
0.152x | +15.19% |
| 2018-12-31 | €7.93 Billion ≈ $9.28 Billion |
€1.05 Billion ≈ $1.22 Billion |
0.132x | -5.74% |
| 2017-12-31 | €6.90 Billion ≈ $8.06 Billion |
€964.10 Million ≈ $1.13 Billion |
0.140x | +54.96% |
| 2016-12-31 | €6.56 Billion ≈ $7.67 Billion |
€592.03 Million ≈ $692.14 Million |
0.090x | -- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more